Page 73 - Read Online

Orsini et al. J Transl Genet Genom 2018;2:16. I https://doi.org/10.20517/jtgg.2018.14 Page 17 of 18

104. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label
interventional trial. Lancet Neurol 2016;15:270-8.
105. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J
Med 2017;376:2011-20.
106. O’Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, et al. Safety and effectiveness of hormonal treatment versus hormonal
treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017;16:33-42.
107. Eunson LH, Rea R, Zuberi SM, Youroukos S, Panayiotopoulos CP, et al. Clinical, genetic, and expression studies of mutations in the
potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol 2000;48:647-56.
108. Rajakulendran S, Schorge S, Kullmann DM, Hanna MG. Episodic ataxia type 1: a neuronal potassium channelopathy. Neurotherapeutics
2007;4:258-66.
109. Wright S, Wallace E, Hwang Y, Maganti R. Seizure phenotypes, periodicity, and sleep-wake pattern of seizures in Kcna-1 null mice.
Epilepsy Behav 2016;55:24-9.
110. Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, et al. Orexin receptor antagonism improves sleep and reduces seizures
in Kcna1-null mice. Sleep 2016;39:357-68.
111. Mishra V, Karumuri BK, Gautier NM, Liu R, Hutson TN, et al. Scn2a deletion improves survival and brain-heart dynamics in the Kcna1-
null mouse model of sudden unexpected death in epilepsy (SUDEP). Hum Mol Genet 2017;26:2091-103.
112. Gardella E, Marini C, Trivisano M, Fitzgerald MP, Alber M, et al. The phenotype of SCN8A developmental and epileptic encephalopathy.
Neurology 2018;91:e1112-24.
113. Anand G, Collett-White F, Orsini A, Thomas S, Jayapal S, et al. Autosomal dominant SCN8A mutation with an unusually mild phenotype.
Eur J Paediatr Neurol 2016;20:761-5.
114. Gardella E, Becker F, Møller RS, Schubert J, Lemke JR, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A
mutation. Ann Neurol 2016;79:428-36.
115. Anderson LL, Thompson CH, Hawkins NA, Nath RD, Petersohn AA, et al. Antiepileptic activity of preferential inhibitors of persistent
sodium current. Epilepsia 2014;55:1274-83.
116. Lopez-Santiago LF, Yuan Y, Wagnon JL, Hull JM, Frasier CR, et al. Neuronal hyperexcitability in a mouse model of SCN8A epileptic
encephalopathy. Proc Natl Acad Sci U S A 2017;114:2383-8.
117. Patel RR, Barbosa C, Brustovetsky T, Brustovetsky N, Cummins TR. Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity
can be targeted with cannabidiol. Brain 2016;139:2164-81.
118. Watanabe Y, Kimura J. Inhibitory effect of amiodarone on Na(+)/Ca(2+) exchange current in guinea-pig cardiac myocytes. Br J Pharmacol
2000;131:80-4.
119. Watanabe Y, Kimura J. Blocking effect of bepridil on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes. Jpn J
Pharmacol 2001;85:370-5.
120. Watanabe Y, Iwamoto T, Shigekawa M, Kimura J. Inhibitory effect of aprindine on Na+/Ca2+ exchange current in guinea-pig cardiac
ventricular myocytes. Br J Pharmacol 2002;136:361-6.
121. Yamakawa T, Watanabe Y, Watanabe H, Kimura J. Inhibitory effect of cibenzoline on Na+/Ca2+ exchange current in guinea-pig cardiac
ventricular myocytes. J Pharmacol Sci 2012;120:59-62.
122. Pena SD, Coimbra RL. Ataxia and myoclonic epilepsy due to a heterozygous new mutation in KCNA2: proposal for a new channelopathy.
Clin Genet 2015;87:e1-3.
123. Jouvenceau A, Eunson LH, Spauschus A, Ramesh V, Zuberi SM, et al. Human epilepsy associated with dysfunction of the brain P/Q-type
calcium channel. Lancet 2001;358:801-7.
124. Xie G, Harrison J, Clapcote SJ, Huang Y, Zhang JY, et al. A new Kv1.2 channelopathy underlying cerebellar ataxia. J Biol Chem
2010;285:32160-73.
125. Imbrici P, Jaffe SL, Eunson LH, Davies NP, Herd C, et al. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and
episodic ataxia. Brain 2004;127:2682-92.
126. Damaj L, Lupien-Meilleur A, Lortie A, Riou É, Ospina LH, et al. CACNA1A haploinsufficiency causes cognitive impairment, autism and
epileptic encephalopathy with mild cerebellar symptoms. Eur J Hum Genet 2015;23:1505-12.
127. Hino-Fukuyo N, Kikuchi A, Arai-Ichinoi N, Niihori T, Sato R, et al. Genomic analysis identifies candidate pathogenic variants in 9 of 18
patients with unexplained West syndrome. Hum Genet 2015;134:649-58.
128. Reinson K, Õiglane-Shlik E, Talvik I, Vaher U, Õunapuu A, et al. Biallelic CACNA1A mutations cause early onset epileptic encephalopathy
with progressive cerebral, cerebellar, and optic nerve atrophy. Am J Med Genet A 2016;170:2173-6.
129. Cramer SW, Popa LS, Carter RE, Chen G, Ebner TJ. Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of
the tottering mouse. J Neurosci 2015;35:5664-79.
130. Zamponi GW. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nat Rev Drug Discov 2016;15:19-34.
131. Song I, Kim D, Choi S, Sun M, Kim Y, et al. Role of the 1G T-type calcium channel in spontaneous absence seizures in mutant mice. J
Neurosci 2004;24:5249-57.
132. Nava C, Dalle C, Rastetter A, Striano P, de Kovel CG, et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nat
Genet 2014;46:640-5.
133. Savelieva I, Camm A. Novel If current inhibitor ivabradine: safety considerations. In: Camm A, Tendera M, editors. Heart rate slowing by If